Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

July 1, 2026

Conditions

Advanced Breast Cancer

Interventions

DRUG

Chidamide，Fulvestrant，angiogenesis inhibitors

chidamide，30mg，po. biw fulvestrant ，500mg， im., d1(c1d15), q4w angiogenesis inhibitors , according to the doctor's advice

Trial Locations (1)

Affiliated Tumor Hospital of Shantou University Medical College, Shantou

All Listed Sponsors

lead

Jundong Wu

OTHER